318 related articles for article (PubMed ID: 35227933)
41. Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study.
Hu N; Qin T; Du X; Wang B; Wang X; Xu Z; Pan L; Qu S; Xiao Z
Med Sci Monit; 2021 Jan; 27():e928454. PubMed ID: 33514682
[TBL] [Abstract][Full Text] [Related]
42. Hypomethylating agents for patients with myelodysplastic syndromes prior to hematopoietic stem cell transplantation: a systematic review and meta-analysis.
Qin Y; Kuang P; Zeng Q; Wu Y; Liu T
Ann Hematol; 2019 Nov; 98(11):2523-2531. PubMed ID: 31637485
[TBL] [Abstract][Full Text] [Related]
43. Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome.
Lee P; Yim R; Yung Y; Chu HT; Yip PK; Gill H
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638574
[TBL] [Abstract][Full Text] [Related]
44. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
[TBL] [Abstract][Full Text] [Related]
45. Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practice.
Bordoni RE; Feinberg BA; Gilmore JW; Haislip S; Jackson JH; Farrelly E; Kim E; Buchner D
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):350-4. PubMed ID: 21816373
[TBL] [Abstract][Full Text] [Related]
46. Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: A systematic review and meta-analysis.
Gao C; Wang J; Li Y; Zhao H; Li R; Hou L; Zhang Y; Tian S; Liang H; Wang C; Chen X; Wang J
Medicine (Baltimore); 2018 Aug; 97(34):e11860. PubMed ID: 30142779
[TBL] [Abstract][Full Text] [Related]
47. Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress.
Venugopal S; Shallis RM; Zeidan AM
Expert Rev Anticancer Ther; 2023; 23(9):903-911. PubMed ID: 37470508
[TBL] [Abstract][Full Text] [Related]
48. Comparison Between Decitabine and Azacitidine for Patients With Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndrome: A Systematic Review and Network Meta-Analysis.
Ma J; Ge Z
Front Pharmacol; 2021; 12():701690. PubMed ID: 34483903
[No Abstract] [Full Text] [Related]
49. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
[TBL] [Abstract][Full Text] [Related]
50. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies.
Stomper J; Rotondo JC; Greve G; Lübbert M
Leukemia; 2021 Jul; 35(7):1873-1889. PubMed ID: 33958699
[TBL] [Abstract][Full Text] [Related]
51. The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs.
Short NJ; Dombret H; Adès L; Kantarjian H
Cancer J; 2022 Jan-Feb 01; 28(1):29-36. PubMed ID: 35072371
[TBL] [Abstract][Full Text] [Related]
52. Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs).
Zeidan AM; Mearns ES; Ng CD; Shah A; Lamarre N; Yellow-Duke A; Alrawashdh N; Yang B; Cheng WH; Bui CN; Svensson A
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):177-186. PubMed ID: 37996264
[TBL] [Abstract][Full Text] [Related]
53. The Prognostic Ability of RAS Pathway-Related Gene Mutations in Patients with Myeloid Neoplasms Treated with Hypomethylating Agents.
Park HS; Son BR; Shin KS; Byeon S; Kim HK; Yang Y; Jeong Y; Han HS; Lee KH; Kwon J
Acta Haematol; 2021; 144(6):649-659. PubMed ID: 34233332
[TBL] [Abstract][Full Text] [Related]
54. Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
Daher-Reyes GS; Merchan BM; Yee KWL
Expert Opin Investig Drugs; 2019 Oct; 28(10):835-849. PubMed ID: 31510809
[No Abstract] [Full Text] [Related]
55. Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).
DeZern AE; Zeidan AM; Barnard J; Hand W; Al Ali N; Brown F; Zimmerman C; Roboz GJ; Garcia-Manero G; Steensma DP; Komrokji RS; Sekeres MA;
Leuk Lymphoma; 2017 Jun; 58(6):1325-1331. PubMed ID: 27774847
[TBL] [Abstract][Full Text] [Related]
56. Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.
Yabushita T; Chinen T; Nishiyama A; Asada S; Shimura R; Isobe T; Yamamoto K; Sato N; Enomoto Y; Tanaka Y; Fukuyama T; Satoh H; Kato K; Saitoh K; Ishikawa T; Soga T; Nannya Y; Fukagawa T; Nakanishi M; Kitagawa D; Kitamura T; Goyama S
Cell Rep; 2023 Sep; 42(9):113098. PubMed ID: 37714156
[TBL] [Abstract][Full Text] [Related]
57. Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism.
Zhao G; Wang Q; Li S; Wang X
Front Oncol; 2021; 11():706030. PubMed ID: 34650913
[TBL] [Abstract][Full Text] [Related]
58. Changes in Apoptotic Pathways in MOLM-13 Cell Lines after Induction of Resistance to Hypomethylating Agents.
Janotka Ľ; Messingerová L; Šimoničová K; Kavcová H; Elefantová K; Sulová Z; Breier A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669837
[TBL] [Abstract][Full Text] [Related]
59. Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines.
Kutyna MM; Loone S; Saunders VA; White DL; Kok CH; Hiwase DK
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834962
[TBL] [Abstract][Full Text] [Related]
60. Hypomethylating agents for elderly patients with acute myeloid leukemia: a PRISMA systematic review and meta-analysis.
Zhang RJ; Zhai JH; Zhang ZJ; Yang LH; Wang MF; Dong CX
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2577-2590. PubMed ID: 33829444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
